A

Actinium Pharmaceuticals Inc
F:7AY1

Watchlist Manager
Actinium Pharmaceuticals Inc
F:7AY1
Watchlist
Price: 1.144 EUR 1.24% Market Closed
Market Cap: 34.1m EUR

Actinium Pharmaceuticals Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Actinium Pharmaceuticals Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
A
Actinium Pharmaceuticals Inc
AMEX:ATNM
Operating Income
-$44.2m
CAGR 3-Years
-17%
CAGR 5-Years
-15%
CAGR 10-Years
-4%
Abbvie Inc
NYSE:ABBV
Operating Income
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$11.3B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Income
$12.1B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.5B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$3.9B
CAGR 3-Years
-17%
CAGR 5-Years
4%
CAGR 10-Years
12%
No Stocks Found

Actinium Pharmaceuticals Inc
Glance View

Market Cap
35.7m EUR
Industry
Biotechnology

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel targeted therapies. The company is headquartered in New York City, New York and currently employs 49 full-time employees. The company went IPO on 2014-03-26. The firm is focused on developing and commercializing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs. The firm develops and markets medicines for relapsed or refractory cancer patients who are treated primarily in large quaternary care hospitals and their catchment areas. Its Iomab-B and Actimab-A product candidates fill the major unmet medical needs in relapsed or refractory acute myeloid leukemia (r/r AML). Iomab-B is a targeted bridging therapy that provides both disease control and conditioning in one agent. Actimab-A is a targeted therapy for fit patients that has demonstrated an impressive extension in survival in a proof-of-concept study and is poised for advanced development in collaboration with the National Cancer Institute (NCI).

7AY1 Intrinsic Value
Not Available
A

See Also

What is Actinium Pharmaceuticals Inc's Operating Income?
Operating Income
-44.2m USD

Based on the financial report for Jun 30, 2025, Actinium Pharmaceuticals Inc's Operating Income amounts to -44.2m USD.

What is Actinium Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-4%

Over the last year, the Operating Income growth was 5%. The average annual Operating Income growth rates for Actinium Pharmaceuticals Inc have been -17% over the past three years , -15% over the past five years , and -4% over the past ten years .

Back to Top